Literature DB >> 27303903

The VapBC1 toxin-antitoxin complex from Mycobacterium tuberculosis: purification, crystallization and X-ray diffraction analysis.

Zuokun Lu1, Han Wang1, Aili Zhang1, Yusheng Tan2.   

Abstract

Mycobacterium tuberculosis, a major human pathogen, encodes at least 88 toxin-antitoxin (TA) systems. Remarkably, more than half of these modules belong to the VapBC family. Under normal growth conditions, the toxicity of the toxin VapC is neutralized by the protein antitoxin VapB. When bacteria face an unfavourable environment, the antitoxin is degraded and the free toxin VapC targets important cellular processes in order to inhibit cell growth. TA systems function in many biological processes, such as in the stringent response, in biofilm formation and in drug tolerance. To explore the structure of the VapBC1 complex, the toxin VapC1 and the antitoxin VapB1 were separately cloned, co-expressed and crystallized. The best crystal was obtained using a crystallization solution consisting of optimized solution with commercial sparse-matrix screen solutions as additives. The crystal diffracted to a resolution of 2.7 Å and belonged to space group P21, with unit-cell parameters a = 59.3, b = 106.7, c = 250.0 Å, β = 93.75°.

Entities:  

Keywords:  Mycobacterium tuberculosis; VapBC; drug target; toxin–antitoxin system

Mesh:

Substances:

Year:  2016        PMID: 27303903      PMCID: PMC4909250          DOI: 10.1107/S2053230X16007603

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  26 in total

Review 1.  The PIN-domain toxin-antitoxin array in mycobacteria.

Authors:  Vickery L Arcus; Paul B Rainey; Susan J Turner
Journal:  Trends Microbiol       Date:  2005-08       Impact factor: 17.079

2.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

Review 3.  Latent tuberculosis infection: myths, models, and molecular mechanisms.

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

4.  The crystal structure of the Rv0301-Rv0300 VapBC-3 toxin-antitoxin complex from M. tuberculosis reveals a Mg²⁺ ion in the active site and a putative RNA-binding site.

Authors:  Andrew B Min; Linda Miallau; Michael R Sawaya; Jeff Habel; Duilio Cascio; David Eisenberg
Journal:  Protein Sci       Date:  2012-11       Impact factor: 6.725

5.  Crystallization of foot-and-mouth disease virus 3C protease: surface mutagenesis and a novel crystal-optimization strategy.

Authors:  James R Birtley; Stephen Curry
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-04-20

6.  Structure and proposed activity of a member of the VapBC family of toxin-antitoxin systems. VapBC-5 from Mycobacterium tuberculosis.

Authors:  Linda Miallau; Michael Faller; Janet Chiang; Mark Arbing; Feng Guo; Duilio Cascio; David Eisenberg
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

Review 7.  Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence.

Authors:  Issar Smith
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

8.  VapC toxins from Mycobacterium tuberculosis are ribonucleases that differentially inhibit growth and are neutralized by cognate VapB antitoxins.

Authors:  Bintou Ahmadou Ahidjo; Diane Kuhnert; Joanna L McKenzie; Edith E Machowski; Bhavna G Gordhan; Vickery Arcus; Garth L Abrahams; Valerie Mizrahi
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

9.  Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes.

Authors:  Deo Prakash Pandey; Kenn Gerdes
Journal:  Nucleic Acids Res       Date:  2005-02-17       Impact factor: 16.971

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.